Southern Connecticut Bancorp Inc. (AMEX: SSE) shares opened sharply higher after a Schedule 13D filing with the SEC revealed that the firm was in talks to sell itself for more than $9.00 per share. Seidman and Associates, which owns a 6.52% stake in the company, questioned why the deal hasn’t gone through and why shareholders were not notified of the impending sale. The activist also nominated their own slate of directors to effect change and take action to unlock shareholder value.

Here’s a copy of the letter:

You have disclosed to me that the Board has received a written letter of intent, in excess of $9.00, to purchase Southern Connecticut Bancorp, Inc. (SSE).  In addition, you represented that the Board was speaking with at least two (2) additional purchasers.  You also represented that the Board has unanimously voted to sell SSE.

Your disclosures to me during our last phone conversation have left me with the impression that you and maybe some of the other Board members may now not be acting in the best interest of all the shareholders.  I cannot understand why the Board has not concluded the SSE sale.  The Board should now make full disclosure with respect to the details of the Board’s negotiations so the shareholders can evaluate the Board’s conduct.

Based upon my many conversations with you, if SSE is not sold, a change in the composition of the Board, in my opinion, is required.  Therefore, I will be nominating Neal S. Axelrod and myself for election to the Board at the next annual shareholders meeting in accordance with Section 1.13 of the SSE Bylaws.  Hopefully we can avoid a costly proxy contest.  Please contact me to discuss the issues raised in this letter.

Please distribute a copy of this letter to all of the SSE Board members.

Related Companies
NewAlliance Bancshares, Inc. (NAL)
Salisbury Bancorp, Inc. (SAL)
Webster Financial Corporation (WBS)

How would you like to know where your kids are at all times? How about receiving alerts when your pets leave the yard? Many people have heard of GPS navigation, but so-called personal location services represent an emerging trend. In fact, a recent research report found that the global market for location based services will grow at a compounded annual growth rate of 104% through 2012.

Personal locators have many unique uses, including:

• Keeping track of children
• Monitoring nomadic pets
• Tracking company vehicles
• Catching speeding teens
• And much more…
  

Location Based Technologies (OTC-BB: LBAS) is a leading manufacturer of these revolutionary new products. The firm has created the smallest single-board GPS unit in the world – about the size of an Oreo – that is set to be released in the first quarter of 2009. The firm has also developed a comprehensive yet easy-to-use software solution to manage these devices from anywhere.

These devices will be made available for under $150 per unit with a basic monthly fee of less than $20 per month with multiple convenient access points. This means big opportunity for Location Based Technologies as these devices take off in popularity. They are just now being released in Europe, but rest assured, the trend will eventually make its way back to the United States.

View Location Based Technologies Research Report

Related Companies
Garmin Ltd. (GRMN)
Trimble Navigation Limited (TRMB)
KVH Industries, Inc. (KVHI)

Icagen, Inc. (NDAQ: ICGN) shares opened sharply higher after a large shareholder demanded changes at the biotechnology company. Xmark Opportunity Partners, which owns a 9.1% stake in the firm, disclosed a letter to the board of directors in a Schedule 13D filing with the SEC. The shareholder pointed out several actions that the company was taking against shareholders and threatened to take action against the board and seek representation if they didn’t back down.

Here’s a copy of the letter:

Xmark Opportunity  Partners,  LLC  ("Opportunity  Partners" or "we" or "us" or "our") is the sole member of the investment manager of Xmark Opportunity Fund, L.P. and Xmark Opportunity Fund, Ltd.  (together,  the "Xmark Funds").  As you are aware, the Xmark Funds are significant shareholders in Icagen, Inc. (the "Company").

As you also are aware,  on September  26, 2008,  Opportunity  Partners filed a Schedule 13D (the "13D")  announcing  its intention to evaluate  closely the  performance  of the  common  shares  of  the  Company,  including,  without limitation,  analyzing and assessing the Company's business, assets, operations, financial condition, capital structure, management and prospects, as well as the fact  that it may,  from  time to time,  evaluate  various  options  in order to attempt to influence the  performance  of the Company and the  activities of its Board of Directors.  On December 1, 2008,  Opportunity  Partners filed Amendment No. 1 to the 13D ("13D Amendment No. 1") disclosing the text of a letter,  dated November 29, 2008 ("Letter 1"), that it had sent to the Board of Directors  that detailed,  among other items,  (a) our efforts to observe a meeting of the Board of Directors,  (b) the Xmark Funds'  accumulation of the Company's common shares and (c) our  strong  belief  that an  extraordinary  transaction  is in the best interest of the Company and its shareholders.

On December 2, 2008,  just day(s) after we sent Letter 1 and filed 13D Amendment No. 1, the Board of Directors adopted a poison pill. To us, the timing of this move is curious and  disturbing  to say the least.  We strongly  believe that this poison pill will deter buyers from the Company to the detriment of the Company's  shareholders and to the benefit of existing  management.  In adopting the poison  pill,  the Board  only  reinforced  our  long-standing  belief  that management is entrenched and the Board is out of touch. Moreover, management and the Board have not recently  announced any cost-cutting  initiatives,  at a time when  companies  all over  the  world,  in every  industry,  are  cutting  costs aggressively.  And, the Company has made only immaterial changes to its material employment agreements.

After  receiving  Letter 1, the Company  offered us an  opportunity to sign a set of confidentiality  agreements to allow us to evaluate steps, if any, that  management  has taken  from a  strategic  perspective.  Unfortunately,  we believe  that the  conditions  of this offer  rendered  it hollow and  illusory. Specifically,  the Company conditioned its disclosure of the Company's strategic plans upon our (i) essentially agreeing to lock-up the shares owned by the Xmark Funds  (which we always  have been  willing to do) and (ii)  agreeing  to remain silent  in  the  public  market  (including  no  proxy  battle),  for  a  period potentially  extending  through the next annual meeting (June 2009). The Company attempted to secure our silence. The proposed  confidentiality  agreements would have  undermined a key purpose of our request -- to speak out and take action if we found that  management  and the Board are not acting  responsibly  and in the best interests of the Company's shareholders.

Rather  than walk away from the  table,  we sought  middle  ground and responded to the Company's  offer with a compromise in the  alternative:  (x) we would agree to lock up the shares owned by the Xmark Funds and remain  silent in the public market through the next annual  meeting if the Company  allowed us to attend a single  meeting  of the Board or (y) we would  agree to a lock up for a period of four (4) months,  so that we would be able to speak at the next annual meeting. In our view, this was a reasonable  compromise.  We wanted a voice; the forum  for  our  voice  -- the  marketplace  or the  boardroom  -- was up to the Company. The Company flatly rejected this proposal.

From this  experience,  we believe that  management and the Board have little or no interest in benefiting the Company's shareholders.  The Company has taken  action  to  quell  public  market  activity  in its  shares,  while  also requesting silence from its most active shareholder. We continue to be amazed by the behavior of the Board,  one that includes  luminaries such as Dr. Charles A. Sanders,  Lead Director of Genentech,  Inc., Anthony B. Evnin,  Managing General Partner of Venrock  Associates,  and Dr. Dennis B. Gillings,  Chairman and Chief Executive Officer of Quintiles Transnational Corp., but, perhaps, nothing should amaze us at this point.

Again,  please be advised that if the Company decides to raise capital in a dilutive  offering,  we will evaluate all available  options to protect the interests  of our limited  partners  and  shareholders,  including,  inter alia, commencing  legal  proceedings  against the Company to seek rescission of such a transaction and/or damages, as well as an action against the Board for breach of fiduciary duty.

Related Companies
Abbott Laboratories (ABT)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)